# CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

> **NCT00323323** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** CHOP
- **DRUG:** Alemtuzumab
- **PROCEDURE:** Plasma Samples

## Key facts

- **NCT ID:** NCT00323323
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2012-08
- **Final completion:** 2016-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323323, "CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00323323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*